GREGORY MATTINGLY: Open Payments
NPI 1215933379 · SAINT CHARLES, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,012,688 in 883 payments from 28 companies in 2025. Trend: 2023 $857,163 · 2024 $842,175 · 2025 $1,012,688
Speaker / faculty: $458,191Honoraria: $253,228Consulting: $155,418Travel & lodging: $123,005Food & beverage: $17,561Speaker / faculty: $5,225
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 123 | $172,023 |
| Neurocrine BioSciences, Inc. | 101 | $130,424 |
| ABBVIE INC. | 113 | $120,029 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 86 | $99,639 |
| Otsuka America Pharmaceutical, Inc. | 107 | $96,398 |
| Supernus Pharmaceuticals, Inc. | 80 | $87,294 |
| E.R. Squibb & Sons, L.L.C. | 70 | $84,047 |
| Alkermes, Inc. | 39 | $47,703 |
| H. Lundbeck A S | 10 | $40,313 |
| Janssen Pharmaceuticals, Inc | 29 | $33,152 |
Products named: Auvelity, INGREZZA, CAPLYTA, VRAYLAR, REXULTI, Qelbree, COBENFY, SPRAVATO.
Industry payments across MO — which companies pay providers there.
